Role of antimicrobial peptides in atopic dermatitis

Suwanchote, Supaporn; Waitayangkoon, Palapun; Chancheewa, Bussabong; Inthanachai, Thananya; Niwetbowornchai, Nattarika; Edwards, Steven W.; Virakul, Sita; Thammahong, Arsa; Kiatsurayanon, Chanisa; Rerknimitr, Pawinee; Chiewchengchol, Direkrit

doi:10.1111/ijd.15814

Cited by 12 publications

(15 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On day 3, the increases were 9.5-, 8.8-, and 6.5-fold for cBD1, cBD3, and cCath, respectively, and on day 10, the respective increases were 9.0-, 5.0-, and 8.0-fold. These findings resemble the dysregulation of HDPs that has been reported in human AD and psoriasis: in data for both AD and psoriasis subjects, protein expression levels of the antimicrobial peptides (AMPs) RNase 7, hBD-2, and hBD-3 were all increased compared to levels in healthy matched controls (Harder et al, 2010;Suwanchote et al, 2022). These similar canine and human findings support the use of the canine model in further elucidating the role of HDPs in AD.…”

Section: In Vivo Skin Barrier Defect Modelsupporting

confidence: 81%

Canine Models of Inflammatory Skin Diseases and Their Application in Pharmacological Research

Gil,

Santoro

2023

Current Protocols

View full text Add to dashboard Cite

The purpose of this article is to provide an overview of existing pharmacological models of canine dermatitis. Canine models of dermatitis have contributed significantly to our current understanding of the pathology of dermatitis and to the development of corresponding pharmacological interventions. Specifically, canine atopic dermatitis (AD) is reviewed here, as it is one of the most common inflammatory skin diseases in dogs. Canine AD also shares clinicopathological features with human AD, making the dog a natural and optimal model for human disease. Thus, pharmacological models of canine AD may be uniquely applicable to human pharmacological research. In this article, particular attention is dedicated to relevant in vivo, in vitro, and ex vivo models of canine AD, skin barrier defect models, pruritus models, and skin immunology models. Additionally, models of superficial pyoderma and food allergy are also discussed. With understanding of findings from canine models, researchers can select the most salient features for future pharmacological drug development. © 2023 Wiley Periodicals LLC.

show abstract

Section: In Vivo Skin Barrier Defect Modelsupporting

confidence: 81%

Canine Models of Inflammatory Skin Diseases and Their Application in Pharmacological Research

Gil,

Santoro

2023

Current Protocols

View full text Add to dashboard Cite

show abstract

“…Host defence peptides (HDPs), or antimicrobial peptides (AMPs), as one of the critical parts of the immune system, can effectively inhibit the pathogenesis of infections and protect the host from inflammation 6 . However, the production of these peptides is often dysregulated by the microbes and inflammatory molecules present in AD lesions 7–9 .…”

Section: Introductionmentioning

confidence: 99%

“…However, the production of these peptides is often dysregulated by the microbes and inflammatory molecules present in AD lesions 7–9 . Recently, research on human HDPs indicate they have some potential advantages for AD treatment, such as their broad spectrum antibacterial action and their immunomodulatory effects, making them a promising candidates in AD patients' management 6 . Amphibians, found in both terrestrial and aquatic environments rich in microbes, are considered excellent natural sources of HDPs/AMPs 10–12 .…”

Section: Introductionmentioning

confidence: 99%

A frog‐derived antimicrobial peptide as a potential anti‐biofilm agent in combating Staphylococcus aureus skin infection

Fei

Wang

Jiang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Staphylococcus aureus (S. aureus), one of the most prevalent bacteria found in atopic dermatitis lesions, can induce ongoing infections and inflammation by downregulating the expression of host defence peptides in the skin. In addition, the emergence of the ‘superbug’ Methicillin‐resistant S. aureus (MRSA) has made the treatment of these infections more challenging. Antimicrobial peptides (AMPs), due to their potent antimicrobial activity, limited evidence of resistance development, and potential immunomodulatory effects, have gained increasing attention as potential therapeutic agents for atopic dermatitis. In this study, we report a novel AMP, brevinin‐1E‐OG9, isolated from the skin secretions of Odorrana grahami, which shows potent antibacterial activity, especially against S. aureus. Based on the characteristics of the ‘Rana Box’, we designed a set of brevinin‐1E‐OG9 analogues to explore its structure–activity relationship. Brevinin‐1E‐OG9c‐De‐NH2 exhibited the most potent antimicrobial efficacy in both in vitro and ex vivo studies and attenuated inflammatory responses induced by lipoteichoic acid and heat‐killed microbes. As a result, brevinin‐1E‐OG9c‐De‐NH2 might represent a promising candidate for the treatment of S. aureus skin infections.

show abstract

“…Interestingly, AMPs such as hBDs, LL-37, and S100A7 have been reported to improve the TJ barrier in vitro in keratinocyte monolayers [ 24 , 25 , 26 , 27 ]. Although accumulated evidence implies a promising role for AMPs in the treatment of AD [ 11 , 40 , 44 ], the precise role of AMPs in the immunopathogenesis of AD remains elusive. In this study, our microarray analysis revealed that the gene expression of IGFBP-5, the parent protein of AMP-IBP5, is lower in skin lesions of patients with AD than in non-lesional skin, suggesting that AMP-IBP5 might be involved in AD pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

The Antimicrobial Peptide AMP-IBP5 Suppresses Dermatitis-like Lesions in a Mouse Model of Atopic Dermatitis through the Low-Density Lipoprotein Receptor-Related Protein-1 Receptor

Nguyen

Peng

Trujillo-Paez

et al. 2023

IJMS

View full text Add to dashboard Cite

The antimicrobial peptide derived from insulin-like growth factor-binding protein 5 (AMP-IBP5) exhibits antimicrobial activities and immunomodulatory functions in keratinocytes and fibroblasts. However, its role in regulating skin barrier function remains unclear. Here, we investigated the effects of AMP-IBP5 on the skin barrier and its role in the pathogenesis of atopic dermatitis (AD). 2,4-Dinitrochlorobenzene was used to induce AD-like skin inflammation. Transepithelial electrical resistance and permeability assays were used to investigate tight junction (TJ) barrier function in normal human epidermal keratinocytes and mice. AMP-IBP5 increased the expression of TJ-related proteins and their distribution along the intercellular borders. AMP-IBP5 also improved TJ barrier function through activation of the atypical protein kinase C and Rac1 pathways. In AD mice, AMP-IBP5 ameliorated dermatitis-like symptoms restored the expression of TJ-related proteins, suppressed the expression of inflammatory and pruritic cytokines, and improved skin barrier function. Interestingly, the ability of AMP-IBP5 to alleviate inflammation and improve skin barrier function in AD mice was abolished in mice treated with an antagonist of the low-density lipoprotein receptor-related protein-1 (LRP1) receptor. Collectively, these findings indicate that AMP-IBP5 may ameliorate AD-like inflammation and enhance skin barrier function through LRP1, suggesting a possible role for AMP-IBP5 in the treatment of AD.

show abstract

Role of antimicrobial peptides in atopic dermatitis

Cited by 12 publications

References 81 publications

Canine Models of Inflammatory Skin Diseases and Their Application in Pharmacological Research

Canine Models of Inflammatory Skin Diseases and Their Application in Pharmacological Research

A frog‐derived antimicrobial peptide as a potential anti‐biofilm agent in combating Staphylococcus aureus skin infection

The Antimicrobial Peptide AMP-IBP5 Suppresses Dermatitis-like Lesions in a Mouse Model of Atopic Dermatitis through the Low-Density Lipoprotein Receptor-Related Protein-1 Receptor

Contact Info

Product

Resources

About